Aranesp

Lea en español

AranespAranesp is the trade name for Darbepoetin alfa, a synthetic version of erythropoietin, which stimulates the production of red blood cells. Aranesp has been used since its approval by the U.S. Food and Drug Administration (FDA) in 2001 to treat patients with anemia, as well as chronic renal failure. It has been frequently prescribed to individuals suffering anemia as a byproduct of chemotherapy.
The FDA has required black box warnings on all sales of Darbepoetin alfa in the United States, citing a number of potential adverse health risks, including:

  • Myocardial infarction, or heart attack, as well as congestive heart failure
    Hypertension (high blood pressure), with increased risk of stroke
  • Venous thromboembolism
  • Thrombosis of vascular access
  • Tumor progression or recurrence

If you experienced side effects after being prescribed Aranesp, GetLegal has the tools and resources to help you find skilled legal representation to protect your rights. Visit our attorney directory, look for your geographic location and find the best lawyer for your situation.

Defective Drugs & Medical Devices Topics

Latest Articles

Avoiding Probate

I often am asked by clients how they can avoid probate. In some situations, it is appropriate to tak…

12 Jul 2019, Friday

What is the Hatch Act and How Did Kellyanne Conway Violate It?

Office of Special Counsel Calls White House Counselor a “Repeat Offender” and Calls for…

25 Jun 2019, Tuesday

TEVA Pharmaceutical Settles Opioid Lawsuit Before Trial

Israeli Drug Company Agrees to Pay $85 Million A second major pharmaceutical company has decided to…

28 May 2019, Tuesday